OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

NASDAQ:OPGN opened at $1.30 on Wednesday. OpGen has a one year low of $1.04 and a one year high of $9.90. The business has a fifty day moving average price of $1.69 and a 200-day moving average price of $2.20.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.